Who we are

We are a molecular diagnostics company developing and commercializing a pipeline of proprietary products for the screening and diagnosis of cancer.

Our products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients.

Our lead product, Epi proColon, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the USA.

Our technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex and Quest Diagnostics.

We are an international company with operations in Europe and the USA.